Liquid biopsy comprehensive genomic profiling of lung cancer in the Italian population: A real-world experience
Authors:
- 4 September 2023
- journal article
- research article
- Published by Elsevier in Lung Cancer
- Vol. 185, 107359
Abstract
No abstract availableKeywords
Funding Information
- Roche SpA
This publication has 56 references indexed in Scilit:
- Impact of TP53 Mutations on Outcome in EGFR-Mutated Patients Treated with First-Line Tyrosine Kinase InhibitorsClinical Cancer Research, 2017
- Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burdenGenome Medicine, 2017
- Emerging concepts in liquid biopsiesBMC Medicine, 2017
- Integrating liquid biopsies into the management of cancerNature Reviews Clinical Oncology, 2017
- The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysisOncotarget, 2016
- Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)The Lancet, 2016
- Biomarker testing and time to treatment decision in patients with advanced nonsmall-cell lung cancerAnnals of Oncology, 2015
- Crizotinib in ROS1-Rearranged Non–Small-Cell Lung CancerNew England Journal of Medicine, 2014
- Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted DrugsJAMA, 2014
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trialThe Lancet Oncology, 2012